Search All UT System Experts

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

  • Robert J. Motzer
  • , Bernard Escudier
  • , Saby George
  • , Hans J. Hammers
  • , Sandhya Srinivas
  • , Scott S. Tykodi
  • , Jeffrey A. Sosman
  • , Elizabeth R. Plimack
  • , Giuseppe Procopio
  • , David F. McDermott
  • , Daniel Castellano
  • , Toni K. Choueiri
  • , Frede Donskov
  • , Howard Gurney
  • , Stéphane Oudard
  • , Martin Richardet
  • , Katriina Peltola
  • , Ajjai S. Alva
  • , Michael Carducci
  • , John Wagstaff
    • Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas C. Gauler, Christian K. Kollmannsberger, Fabio A. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir

Research output: Contribution to journal › Article › peer-review

271 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science